Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Thanx for your patience as we [...]

Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund.
Thanx for your patience as we catch-up.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.

Siluria Technologies (San Francisco, CA) a development-stage biofuels company focused on methane conversion, closed a $20M Series B financing. Participants include Wellcome Trust, Alloy Ventures, Arch Venture Partners, Kleiner Perkins, Altitude Life Science Ventures, Lux Capital and Presidio Ventures.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

Oncofactor (Seattle, WA) a development stage biopharmaceutical company focused on oncology, closed a $2.1M Series A financing. Participants include Accelerator, OVP Venture Partners, Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners and WRF Capital.

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.